Recursion Pharmaceuticals, Inc. RXRX Net Income
Net Income at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s net income?
- Recursion Pharmaceuticals, Inc. (RXRX) reported net income of -$117.5M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s net income changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s net income increased by 42.0% year-over-year, from -$202.49M to -$117.5M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s net income?
- Over 4 years (2021 to 2025), Recursion Pharmaceuticals, Inc.'s net income has grown at a 36.4% compound annual growth rate (CAGR), from -$186.48M to -$644.76M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.